Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 06, 2026
RTX Corporation (RTX) Gains +4.3% as Defense Contracts Fuel Growth

RTX Corporation (RTX) Gains +4.3% as Defense Contracts Fuel Growth

Key Takeaways

  • RTX shares have gained approximately 4.3% over the past 30 days, reflecting steady investor confidence driven by new defense contracts and European production expansion.
  • Raytheon secured a $1.1 billion U.S. Navy contract for AIM-9X Block II missiles in late June and announced plans to double Stinger missile output through European partnerships.
  • Analyst consensus remains broadly positive, with a "Moderate Buy" rating and an average price target around $216, implying further upside from current levels.
  • Q2 2026 earnings are expected on July 23, with Jefferies projecting adjusted EPS of $1.74 versus a $1.67 consensus estimate.
  • Expanding NATO collaboration on AMRAAM missile co-production and growing global defense budgets provide a supportive long-term demand backdrop.

Current Market Snapshot

RTX Corporation has traded within a relatively constructive range through mid-July 2026, with shares hovering near the $193–$200 band after pulling back modestly from the $201 level touched earlier in the month. The stock sits above its 50-day moving average of approximately $185, indicating near-term technical strength, while remaining below its 52-week high of $214.50. With a market capitalization near $260 billion, RTX continues to attract institutional interest — Dimensional Fund Advisors, among others, increased its position during the most recent quarter. The broader aerospace and defense sector has benefited from sustained global security spending and recovering commercial aviation activity, both of which directly support RTX's multi-segment revenue base. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

RTX Corporation (RTX) Business Overview and Competitive Position

RTX Corporation, headquartered in Arlington, Virginia, is one of the world's largest aerospace and defense companies, formed through the 2020 merger of Raytheon Company and United Technologies Corporation. The company operates through three principal segments: Raytheon, a premier provider of missile systems, air defense platforms, sensors, and advanced weapons; Pratt & Whitney, a leading manufacturer of commercial and military aircraft engines, including the Geared Turbofan (GTF) family; and Collins Aerospace, which supplies avionics, aerostructures, interiors, and integrated aircraft systems. With 2025 sales exceeding $88 billion and a global workforce of more than 180,000, RTX occupies a strategic position across both defense and commercial aerospace supply chains. The company's deep backlog of long-duration government contracts provides revenue visibility, while its commercial aftermarket business generates recurring high-margin service income tied to global fleet utilization.

Recent Developments Driving RTX

Several verified catalysts have shaped RTX's performance over the past 30 days. In late June, Raytheon secured a $1.1 billion contract from the U.S. Navy to produce AIM-9X Block II missiles, reinforcing the segment's order momentum. On July 7, Raytheon announced a partnership with Germany's Diehl Defence and Dutch suppliers to double Stinger missile production capacity, with final assembly taking place in the Netherlands — a direct response to rising European demand. The same day, Raytheon disclosed NATO-funded feasibility studies to qualify additional European suppliers for AMRAAM missile components, a move designed to expand production and accelerate deliveries.

On the commercial side, Pratt & Whitney's F119 engine surpassed one million flight hours powering the LMT F-22 Raptor, highlighting the durability of RTX's military engine portfolio. The company also confirmed a quarterly dividend of $0.73 per share, marking continued capital returns alongside capacity investments. Jefferies reiterated its Buy rating and $220 price target on July 8, citing confidence in second-half margin expansion. Options activity surged, particularly in July $200 call contracts, reflecting short-term bullish positioning ahead of the upcoming earnings release. These developments collectively signal that RTX is converting geopolitical defense demand into tangible contract growth while managing commercial aerospace headwinds such as supply chain constraints and tariff exposure.

2026 Outlook and What Investors Should Watch

RTX's forward trajectory in 2026 will likely be shaped by several interconnected factors. The most immediate catalyst is the Q2 2026 earnings report scheduled for July 23, where investors will scrutinize segment-level margins at Raytheon and Pratt & Whitney, progress on defense framework agreements with the Department of Defense, and any updates to full-year guidance currently set at $6.60–$6.80 in adjusted EPS on $92–$93 billion in sales. Analysts at Jefferies project free cash flow of approximately $8.6 billion for the year, a metric closely watched given the capital-intensive nature of scaling missile and engine production.

Beyond earnings, European defense cooperation represents a multi-year growth avenue. The feasibility studies for expanding AMRAAM co-production and the Stinger production doubling initiative both align with NATO's drive toward greater industrial self-sufficiency. Domestically, the final fiscal 2027 defense budget and the pace at which OBBBA funds flow into procurement programs could materially influence Raytheon's order book. On the commercial aerospace side, investors should monitor aftermarket shop visit trends at Pratt & Whitney, particularly for GTF engines, where reliability improvements and faster turnaround times could boost high-margin service revenue. Key risks include persistent supply chain bottlenecks in rocket motors and microelectronics, potential tariff impacts on imported materials, and any softening in global air travel demand that could pressure Collins Aerospace and Pratt & Whitney's commercial businesses. From what I see, this is important because it ties directly into the broader defense spending trends.

Trending AI Robots

One resource I turn to for additional perspective on market dynamics is Tickeron's Trending AI Robots. It surfaces top-performing AI-powered trading strategies across various timeframes and includes transparent performance metrics, which can help complement traditional fundamental analysis when evaluating names like RTX.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RTX

RTX sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for RTX moved above the 200-day moving average on July 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 23, 2026. You may want to consider a long position or call options on RTX as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RTX just turned positive on July 23, 2026. Looking at past instances where RTX's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RTX advanced for three days, in of 344 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 324 cases where RTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RTX broke above its upper Bollinger Band on July 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. RTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.515) is normal, around the industry mean (10.229). P/E Ratio (39.139) is within average values for comparable stocks, (64.997). Projected Growth (PEG Ratio) (2.782) is also within normal values, averaging (8.314). Dividend Yield (0.013) settles around the average of (0.016) among similar stocks. P/S Ratio (3.239) is also within normal values, averaging (35.964).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 38.26B. The market cap for tickers in the group ranges from 4.49 to 1.43T. SPCX holds the highest valuation in this group at 1.43T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was 8%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 2%. VOYG experienced the highest price growth at 54%, while VWAV experienced the biggest fall at -38%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 29%. For the same stocks of the Industry, the average monthly volume growth was -13% and the average quarterly volume growth was 12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 67
Price Growth Rating: 56
SMR Rating: 79
Profit Risk Rating: 72
Seasonality Score: -22 (-100 ... +100)
View a ticker or compare two or three
RTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers

Industry AerospaceDefense

Profile
Details
Industry
N/A
Address
1000 Wilson Boulevard
Phone
+1 781 522-3000
Employees
185000
Web
https://www.rtx.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
RTX Corporation (RTX) Gains +4.3% as Defense Contracts Fuel Growth